This is a summary of the European public assessment report (EPAR) for Sycrest. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sycrest.
Therapeutic Indication
### Therapeutic indication Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Therapeutic Area (MeSH)
N/AATC Code
N05AH05
ATC Item
asenapine
Pharmacotherapeutic Group
Psycholeptics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| asenapine maleate | N/A | Asenapine Maleate |
| asenapine (as maleate) | N/A | asenapine (as maleate) |
EMA Name
Sycrest
Medicine Name
Sycrest
Aliases
N/ANo risk management plan link.
